Iambic Therapeutics, Inc. (IAM) · Oct 16, 2026 · Share issuance
IPO completed — IPO closed October 16, 2026
Iambic’s IPO has closed, but this 8-K is mainly corporate housekeeping: no new clinical data, financing detail, or pipeline update.
Iambic is a newly public, clinical-stage AI drug-discovery company building a platform that combines AI models with automated laboratory experimentation; its lead program, IAM1363, is in Phase 1/1b testing for HER2-altered solid tumors, with additional candidates still preclinical.
This filing completes the IPO’s legal mechanics, rather than advancing the pipeline. Iambic filed an amended and restated certificate of incorporation in connection with the IPO. 〔0〕 It also adopted amended and restated bylaws effective the same day. 〔1〕
The information is already largely known. The IPO had been priced at $16 per share and was expected to close on October 16, so this 8-K confirms a scheduled transaction rather than revealing a new financing outcome or a change in strategy.
There is no fresh operating signal here. The filing provides no new clinical readout, cash balance, runway update, program milestone, or guidance; the Item 7.01 section only describes the company’s future disclosure channels.
Bottom line: This is an administrative confirmation that Iambic is now public, not a new read on whether its AI platform or cancer pipeline is working. The next meaningful business signal should come from IAM1363’s clinical development, not this filing〔2〕
IAM1363 Phase 1/1b clinical updates
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!